课题基金 / 基金详情

O-GLCNAC MODIFICATION OF SIGNALING EFFECTORS IN 3T3-L1 NORMAL VS INSULIN

O-GLCNAC MODIFICATION OF SIGNALING EFFECTORS IN 3T3-L1 NORMAL VS INSULIN
O-GLCNAC 对 3T3-L1 正常与胰岛素信号效应器的修饰
批准号:
8169736
负责人:
DAVID H STOKOE
金额:
$0.18万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-12 至 2011-05-31

项目摘要

项目成果

DAVID H STOKOE的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In many models of hyperglycemia induced insulin resistance, a signaling defect at the level of insulin stimulated Akt activation has been demonstrated. Increased levels of O-GlcNAc have been causally linked to insulin signaling defects, but the specific proteins and sites of modification mediating these negative effects are not known. PI 3-kinase is upstream of Akt activation. Potentially, increased O-GlcNAc in the insulin resistant state on molecules involved in this pathway influence insulin signals. The O-GlcNAc modification state of molecules involved in this pathway (e.g. Akt, and PDK1) in normal vs. insulin resistant states will be examined. If specific proteins are found to be modified, site mapping analysis will be performed using a technique (BEMAD) newly developed at the UCSF mass spec facility. Ultimately, mapped sites will be tested for regulatory functions in the context of insulin signaling.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploiting the P13 Kinase Pathway in Human Glioma Therapy
PHOSPHORYLATION OF HAMARTIN AND TUBERIN, THE PRODUCTS OF THE TSC1 AND TSC2 TUMO
PDK-1 as an attractive cancer therapeutic
O-GLCNAC MODIFICATION OF SIGNALING EFFECTORS IN 3T3-L1 NORMAL VS INSULIN